# EDGAR Filing Document

**Accession Number:** 0001936258
**File Stem:** 0001193125-23-016222
**Filing Date:** 2023-1
**Character Count:** 2678
**Document Hash:** 80bfd9995affa9efe602392abc4c65d2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-016222.hdr.sgml**: 20230228

**ACCESSION NUMBER**: 0001193125-23-016222

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230126

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NewAmsterdam Pharma Co N.V.
- **CENTRAL INDEX KEY:** 0001936258
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** GOOIMEER 2-35
- **CITY:** NARRDEN
- **STATE:** P7
- **ZIP:** 1411 DC
- **BUSINESS PHONE:** 35 206 2971

**MAIL ADDRESS:**
- **STREET 1:** GOOIMEER 2-35
- **CITY:** NARRDEN
- **STATE:** P7
- **ZIP:** 1411 DC

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NewAmsterdam Pharma Co B.V.
- **DATE OF NAME CHANGE:** 20220701

NewAmsterdam Pharma Company N.V.

Gooimeer 2-35

1411 DC Naarden

The Netherlands

January 26, 2023

**Via EDGAR** 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3561

Attn: Cindy Polynice

Joe McCann

---

| | |
|:---|:---|
| **Re:** | **NewAmsterdam Pharma Company N.V.** |
|  | **Amendment No. 1 to Registration Statement on Form F-1**<br> **Filed January 17, 2023** |
|  | **File No. 333-268888** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Securities Act"), NewAmsterdam Pharma Company N.V. (the "Company") hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form F-1 (the "Registration Statement") be accelerated by the Securities and Exchange Commission so that the Registration Statement will be declared effective under the Securities Act at 4:00 p.m. Eastern Time on January 30, 2023, or as soon thereafter as is practicable, or such other time as the Company or its counsel, Covington & Burling LLP, may request by telephone that such Registration Statement be declared effective.

We respectfully request that we be notified of such effectiveness by a telephone call to Kerry S. Burke of Covington & Burling LLP at (202) 662-5297 and that such effectiveness also be confirmed in writing.

---

| | |
|:---|:---|
| Respectfully, | Respectfully, |
| **NewAmsterdam Pharma Company N.V.** | **NewAmsterdam Pharma Company N.V.** |
| By: | /s/ Michael Davidson |
| Name: Michael Davidson<br> Title: Chief Executive Officer and Executive Director | Name: Michael Davidson<br> Title: Chief Executive Officer and Executive Director |

---

cc: Kerry S. Burke, Covington & Burling LLP